Transcription factor KLF4 inhibits lung cancer cell growth and metastasis by promoting CYLD-induced TEK...

Area of Science:

• Oncology
• Molecular Biology
• Gene Regulation

Background:

• Cylindromatosis (CYLD) acts as a tumor suppressor in lung cancer (LC) progression.
• The precise molecular mechanisms underlying CYLD's role in LC require further investigation.

Purpose of the Study:

• To elucidate the molecular mechanism of CYLD in lung cancer progression.
• To investigate the regulatory axis involving KLF4, CYLD, and TEK in LC.

Main Methods:

• Gene expression analysis (qRT-PCR, Western blot) of CYLD, KLF4, and TEK.
• Molecular interaction studies (ChIP, dual-luciferase, Co-IP) to confirm regulatory relationships.
• Functional assays (cell proliferation, migration, invasion, apoptosis) and in vivo xenograft models in mice.

Main Results:

• CYLD expression was significantly downregulated in LC tissues and cells.
• KLF4 directly binds to the CYLD promoter, enhancing its transcription and expression.
• KLF4 overexpression inhibited LC cell proliferation, migration, and invasion while promoting apoptosis, effects dependent on CYLD.
• CYLD deubiquitination increased TEK expression, and TEK silencing reversed CYLD's inhibitory effects on LC growth and metastasis.
• In vivo studies confirmed KLF4 suppresses tumor growth via the CYLD/TEK axis.

Conclusions:

• The KLF4-activated CYLD pathway suppresses lung cancer cell growth and metastasis.
• This repression occurs through the enhancement of TEK deubiquitination.
• The KLF4/CYLD/TEK axis represents a novel regulatory pathway and potential therapeutic target for lung cancer.